» Articles » PMID: 35157714

Increased Risk of High-grade Prostate Cancer Among Testicular Cancer Survivors

Overview
Journal PLoS One
Date 2022 Feb 14
PMID 35157714
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Testicular cancer survivors (TCS) have an increased risk of additional cancers, including prostate cancer. Our understanding of the natural history of prostate cancer in testicular cancer survivors is very limited due to its rare incidence.

Methods: Using the Surveillance, Epidemiology, and End Results (SEER) Registry from 1978 to 2011, we identified 282 TCS with subsequent prostate cancer and examined the tumor grade and clinical outcomes in contrast to men with primary prostate cancer in the general population.

Results: TCS with a subsequent prostate cancer diagnosis were more likely to be diagnosed at a younger age than men with primary prostate cancer (65.2% vs. 37.6% for age ≤65, 34.8% vs. 62.4% for age >65, p<0.001) and were more likely to have grade III/IV tumors (46.2% vs. 37.0%, p<0.002). Longer latency between testicular and prostate cancer diagnoses was associated with a higher risk of grade III/IV (p<0.001) cancer. Despite the increased risk for high-grade tumors, 10-year prostate cancer-specific survival and overall survival were not significantly different between TCS and men with primary prostate cancer. Based on the available information in SEER, we found that prior history of radiotherapy for testicular cancer had no impact on tumor grade or survival outcomes.

Conclusions: Prostate cancer in TCS was more likely to be diagnosed at a younger age and with higher grades. Risks of grade III/IV disease increased with longer latency between testicular and prostate cancer diagnoses. Radiotherapy for testicular cancer did not appear to have a significant impact on the outcome of subsequent prostate cancer.

References
1.
Richiardi L, Scelo G, Boffetta P, Hemminki K, Pukkala E, Olsen J . Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer. 2006; 120(3):623-31. DOI: 10.1002/ijc.22345. View

2.
Jones W, Fossa S, Mead G, Roberts J, Sokal M, Horwich A . Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005; 23(6):1200-8. DOI: 10.1200/JCO.2005.08.003. View

3.
Fung C, Fossa S, Milano M, Oldenburg J, Travis L . Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2013; 31(30):3807-14. PMC: 3795890. DOI: 10.1200/JCO.2013.50.3409. View

4.
Travis L, Fossa S, Schonfeld S, McMaster M, Lynch C, Storm H . Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005; 97(18):1354-65. DOI: 10.1093/jnci/dji278. View

5.
Jensen M, Rugbjerg K, de Fine Licht S, Johansen C, Schmiegelow K, Andersen K . Endocrine Late Effects in Survivors of Cancer in Adolescence and Young Adulthood: A Danish Population-Based Cohort Study. JAMA Netw Open. 2019; 1(2):e180349. PMC: 6324403. DOI: 10.1001/jamanetworkopen.2018.0349. View